Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hajime Takashima

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Topics in Medicinal Chemistry|April 8, 2003
Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug designHajime Takashima
Journal of Computational Chemistry|March 23, 2021
Generalized-ensemble method study: A helix-mimetic compound inhibits protein-protein interaction by long-range and short-range intermolecular interactionsJunichi Higo, Hajime Takashima, Yoshifumi Fukunishi, et al.
Microbiology Spectrum|June 1, 2022
TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on <i>In Vitro</i> Activity of Meropenem against Carbapenem-Resistant EnterobacteriaceaeIppei Yoshida, Iichiro Takata, Kiyoko Fujita, et al.
The Journal of Antibiotics|January 6, 2022
TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivoKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2022
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein-Protein Interaction between CTLA-4 and B7-1Kumiko Tsuihiji, Eiji Honda, Kanehisa Kojoh, et al.
The Journal of Antibiotics|November 27, 2021
TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against EnterobacteriaceaeKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
ACS Omega|October 18, 2021
Visualized and Quantitative Conformational Analysis of PeptidomimeticsHajime Takashima, Atsushi Yoshimori, Eiji Honda, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|February 8, 2022
Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection modelKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
Journal of Computational Chemistry|September 6, 2002
A novel parallel algorithm for large-scale Fock matrix construction with small locally distributed memory architectures: RT parallel algorithmHajime Takashima, So Yamada, Shigeru Obara, et al.
Molecular Cancer Therapeutics|November 18, 2003
A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155Yasuji Ueda, Takehiro Yamagishi, Kazunori Samata, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Topics in Medicinal Chemistry|April 8, 2003
Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug designHajime Takashima
Journal of Computational Chemistry|March 23, 2021
Generalized-ensemble method study: A helix-mimetic compound inhibits protein-protein interaction by long-range and short-range intermolecular interactionsJunichi Higo, Hajime Takashima, Yoshifumi Fukunishi, et al.
Microbiology Spectrum|June 1, 2022
TP0586532, a Novel Non-Hydroxamate LpxC Inhibitor: Potentiating Effect on <i>In Vitro</i> Activity of Meropenem against Carbapenem-Resistant EnterobacteriaceaeIppei Yoshida, Iichiro Takata, Kiyoko Fujita, et al.
The Journal of Antibiotics|January 6, 2022
TP0586532, a non-hydroxamate LpxC inhibitor, reduces LPS release and IL-6 production both in vitro and in vivoKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
Pharmaceuticals (Basel, Switzerland)|December 23, 2022
Rational Strategy for Designing Peptidomimetic Small Molecules Based on Cyclic Peptides Targeting Protein-Protein Interaction between CTLA-4 and B7-1Kumiko Tsuihiji, Eiji Honda, Kanehisa Kojoh, et al.
The Journal of Antibiotics|November 27, 2021
TP0586532, a non-hydroxamate LpxC inhibitor, has in vitro and in vivo antibacterial activities against EnterobacteriaceaeKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
ACS Omega|October 18, 2021
Visualized and Quantitative Conformational Analysis of PeptidomimeticsHajime Takashima, Atsushi Yoshimori, Eiji Honda, et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|February 8, 2022
Pharmacodynamic target assessment and prediction of clinically effective dosing regimen of TP0586532, a novel non-hydroxamate LpxC inhibitor, using a murine lung infection modelKiyoko Fujita, Iichiro Takata, Ippei Yoshida, et al.
Journal of Computational Chemistry|September 6, 2002
A novel parallel algorithm for large-scale Fock matrix construction with small locally distributed memory architectures: RT parallel algorithmHajime Takashima, So Yamada, Shigeru Obara, et al.
Molecular Cancer Therapeutics|November 18, 2003
A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155Yasuji Ueda, Takehiro Yamagishi, Kazunori Samata, et al.
Pageof 2